Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that management will participate at both the upcoming KBC Healthcare Conference and the Leerink Partners Roundtable Series: Rare Disease & Oncology.
Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that management will participate at both the upcoming KBC Healthcare Conference and the Leerink Partners Roundtable Series: Rare Disease & Oncology.
The KBC Healthcare Conference will take place in New York, NY on September 27, 2018.
Celyad to Participate at Upcoming Healthcare Conferences
The Leerink Partners Roundtable Series: Rare Disease & Oncology will take place in New York, NY on October 2-3, 2018 and the Company is scheduled to present on Wednesday, October 3 at 4:00 p.m. ET. A live webcast of the presentation can be accessed at http://wsw.com/webcast/leerink31/cyad/. An archived webcast recording will also be available under Events & Webcasts in the Investors section of the Company’s website.
